Kardigan
Kardigan develops cardiovascular medicines that target specific biological drivers of heart disease and the patient groups most likely to respond.
$300MSeries A
LeadPA
Perceptive Advisors
Activity from announced rounds
Activity in this selectionJan 31, 2025 · Jan 1, 2025
Perceptive Advisors is the healthcare investment manager named in Superluminal’s financing and retained company records.
Recorded funding activity
Superluminal develops small-molecule medicines using structural and experimental methods. Vaderis develops an oral treatment for hereditary hemorrhagic telangiectasia, while Imperative develops thromboembolic interventions. The manager remains separate from the Xontogeny venture arm.
- Rounds participated in
- 1
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $300M 1 disclosed · full round size, not this investor’s share